Pionyr Immunotherapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 56
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 13

Pionyr Immunotherapeutics General Information

Description

Developer of cancer immunotherapies designed to target the tumor microenvironment to enhance the body's antitumor immunity. The company's immunotherapies enhance the immune system's anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity, enabling patients to combat cancer, particularly in combination with checkpoint inhibitors.

Contact Information

Formerly Known As
Precision Immune
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2 Tower Place
  • Suite 800
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Pionyr Immunotherapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pionyr Immunotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 00000 Completed Clinical Trials - General
6. Early Stage VC 01-Jul-2020 00000 00000 00000 Completed Clinical Trials - General
5. Early Stage VC (Series B) 28-Mar-2018 0000 000.00 Completed Clinical Trials - General
4. Early Stage VC (Series A1) 04-Jan-2017 000 00.00 000.00 Completed Clinical Trials - General
3. Early Stage VC (Series A) 08-May-2015 00.000 00.000 00.000 Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
1. Accelerator/Incubator Completed Pre-Clinical Trials
To view Pionyr Immunotherapeutics’s complete valuation and funding history, request access »

Pionyr Immunotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A1 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 2,094,892 $0.000100 $0.06 $0.71 $0.71 1x $0.71 3.45%
To view Pionyr Immunotherapeutics’s complete cap table history, request access »

Pionyr Immunotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cancer immunotherapies designed to target the tumor microenvironment to enhance the body's antitumor immuni
Drug Discovery
South San Francisco, CA
56 As of 2021
00000
000000 - 000 00000

0000000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
San Carlos, CA
000 As of 0000
00000
00000000 00000

00000000

u fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia d
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pionyr Immunotherapeutics Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Iovance Biotherapeutics Corporation San Carlos, CA 000 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000 000000 Venture Capital-Backed South San Francisco, CA 000 00000 00000000000 00000
000000 00000000000 Venture Capital-Backed Plymouth Meeting, PA 0 000.00 00000000000 000.00
You’re viewing 5 of 48 competitors. Get the full list »

Pionyr Immunotherapeutics Patents

Pionyr Immunotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10836828-B2 Anti-trem1 antibodies and related methods Active 06-Feb-2019 000000000
US-20200255529-A1 Anti-trem1 antibodies and related methods Granted 06-Feb-2019 000000000
US-20210101983-A1 Anti-trem1 antibodies and related methods Pending 06-Feb-2019 000000000
CA-3128053-A1 Anti-trem1 antibodies and related methods Pending 06-Feb-2019 000000000
US-20200247889-A1 Compositions and methods for disabling myeloid cells expressing trem1 Pending 08-Aug-2017 C07K16/2818

Pionyr Immunotherapeutics Executive Team (9)

Name Title Board Seat Contact Info
Steven James President, Chief Executive Officer & Board Member
Monte Montgomery Chief Financial Officer & Senior Vice President
Kevin Baker Ph.D Senior Vice President & Chief Development Officer
Michel Streuli Ph.D Senior Vice President & Chief Scientific Officer
Alicia Levey Ph.D Senior Vice President & Chief Business Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Pionyr Immunotherapeutics Board Members (10)

Name Representing Role Since
Carol Gallagher MD New Enterprise Associates Board Member 000 0000
Joshua Resnick MD SV Health Investors Board Member 000 0000
Michael Powell Ph.D Sofinnova Investments Board Member 000 0000
Michael Quigley Ph.D Gilead Sciences Board Member 000 0000
Michael Ross Ph.D SV Health Investors Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Pionyr Immunotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pionyr Immunotherapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gilead Sciences Corporation Minority 000 0000 000000 0
New Enterprise Associates Venture Capital Minority 000 0000 000000 0
Sofinnova Investments Venture Capital Minority 000 0000 000000 0
Trinitas Capital (Beijing) PE/Buyout Minority 000 0000 000000 0
Vida Ventures (Boston) Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »